Immunicum AB (publ) Provides Update on Ilixadencel Clinical Development Program
April 03 2018 - 2:00AM
Press Release
3 April 2018
Immunicum AB (publ) Provides Update on Ilixadencel Clinical
Development Program
Immunicum AB
(publ; IMMU.ST) provided today an update on planned, ongoing and
previously completed clinical trials for its lead program,
ilixadencel. Ilixadencel is a cell-based treatment with therapeutic
potential as a component of combination regimens for a range of
solid tumor cancers. It has been tested in more than 90 cancer
patients to date.
"We proceed according to plan with
our ongoing clinical trials for ilixadencel in kidney and
gastrointestinal stromal cancer patients. In addition, over the
last several months we have achieved important progress in the
development of the study protocol for the multi-indication
checkpoint inhibitor combination trial. We look forward to start
enrolling patients in that trial this year," said Carlos de Sousa,
CEO of Immunicum. "Ilixadencel has broad potential as a key
component of todays' innovative combination therapies to treat many
different forms of solid tumor cancers. Our primary goal is to
advance ilixadencel in indications with the greatest medical need
and strategic potential."
Trial in
preparation
Multi-indication
Phase Ib/II Checkpoint Inhibitor Combination Trial
Based on its mode of action and the preclinical proof-of-concept
data announced in 2017, Immunicum sees significant potential for
ilixadencel as an immune primer in combination with checkpoint
inhibitors (CPIs). The Company conducted an in-depth analysis of
solid tumor cancers with high unmet medical need and limited
sensitivity to CPIs and selected head & neck cancer, gastric
adenocarcinoma and non-small cell lung cancer. After meetings with
external experts and health authorities, the study protocol is now
in its final stages. Immunicum expects to submit the trial
documentation first to the US Food and Drug Administration,
followed by submission for ethical review, during the second
quarter 2018. The Company plans to enroll the first patient during
the second half of 2018. The Company will provide updates on the
Phase Ib portion of the study. These updates are expected to start
during the first half of 2019 and to continue over the course of
the year.
"We are very excited about our
progress preparing for this important study, which will be
conducted primarily at clinics in the US, the most important market
for cutting-edge immuno-oncology treatments," added Peter Suenaert,
Chief Medical Officer of Immunicum.
Ongoing clinical
trials
MERECA Phase II
Trial
As previously reported, patient recruitment has been completed and
a total of 88 newly diagnosed mRCC patients have been randomized
into the trial conducted at 28 centers in eight European countries
and the US. The 18-month follow-up period for the last patient
treated will be completed in mid-year 2019, which will allow
communication of the main findings of the trial in the 3Q
2019. To iterate past communications, the study protocol does
not permit interim data analysis. It is critical to the success of
the trial and the integrity of the data for regulatory and
corporate development purposes that Immunicum maintain the protocol
and not invalidate the MERECA data.
Gastrointestinal
Stromal Tumors (GIST) Phase I/II Trial
The Company's collaborators at the Karolinska University Hospital
have enrolled a total of 5 patients in the clinical Phase I/II
study with ilixadencel in patients with Gastrointestinal Stromal
Tumors (GIST). GIST is a very rare and complex disease with only
200 cases diagnosed in Sweden every year. It remains a severe
cancer indication in desperate need of new therapeutics. Immunicum
expects to announce the analysis of primary outcome measures of
safety and tolerability, as well as initial secondary outcomes on
efficacy, tumor response and progression-free survival in 2019.
Completed
clinical trials
Hepatocellular
Carcinoma (HCC) Phase I/II Trial
In September 2017, Immunicum announced the most important topline
results from the completed Phase I/II safety and tolerability
clinical trial of ilixadencel in 18 advanced liver cancer patients.
Ilixadencel was shown to be safe and well tolerated in these
patients when given both as a single treatment and in combination
with the current first line standard treatment, sorafenib. In
addition, the results provide evidence of tumor-specific immune
activation in the majority of evaluable patients. Based on these
positive data, Immunicum will continue to explore the potential of
advancing to the next stage of clinical development in this
indication based on different strategic and financial
opportunities. The Company is preparing a manuscript describing the
previously announced data in more detail for submission to a
scientific journal for publication.
Renal Cell
Carcinoma (mRCC) Phase I/II Trial
The trial initiated in 2012 tested ilixadencel in combination with
standard of care in 12 newly diagnosed metastatic renal cell
carcinoma (mRCC) patients. The last patient was treated in August
2013. Immunicum has followed the surviving patients over the course
of the last 5 years and as of January 18, 2018, which is the final
update, three of the 12 patients were still alive. The final median
overall survival for the patients is 48 months, which compares
favorably with published historical data of 15-16 months overall
survival for newly diagnosed mRCC patients treated with sunitinib
alone.
About
ilixadencel
Ilixadencel, a cell therapy product, is an off-the-shelf cancer
immune primer, developed for the treatment of solid tumors. Its
active ingredient is activated allogeneic dendritic cells, derived
from healthy blood donors. Intratumoral injection of these cells
generates an inflammatory response which in turn leads to
tumor-specific activation of the patient's cytotoxic T-cells.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO,
Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer and Joanne
Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ)
Immunicum is establishing a unique
immuno-oncology approach through the development of allogeneic,
off-the-shelf cell-based therapies. Our goal is to improve survival
outcomes and quality of life by priming the patient's own immune
system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the
potential to become a backbone component of modern cancer
combination treatments in a variety of solid tumor indications.
Founded and based in Sweden, Immunicum is publicly traded on the
Nasdaq Stockholm. www.immunicum.com
20180403_Immunicum_ClinDevUpdate_ENG_FINAL
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024